Samalizumab

Last updated

Samalizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD200
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6542H10086N1702O2102S46
Molar mass 147687.22 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Samalizumab is a humanized monoclonal antibody designed for oncology indications. [1] Samalizumab is a recombinant humanized monoclonal antibody that targets the immunoregulatory protein CD200. Results from a Phase I study indicated the drug has potential for use in treating cancers including chronic lymphocytic leukemia. [2]

Samalizumab was developed by Alexion Pharmaceuticals.

References

  1. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.
  2. ↑ Mahadevan D, Lanasa MC, Farber C, Pandey M, Whelden M, Faas SJ, et al. (August 2019). "Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200". Journal for Immunotherapy of Cancer. 7 (1): 227. doi: 10.1186/s40425-019-0710-1 . PMID   31443741.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.